☰

Joseph P. Antonios

Affiliations: 
2007-2019 Neuroscience University of California, Los Angeles, Los Angeles, CA 
 2019- Neurosurgery Yale University, New Haven, CT 
Area:
Immunology, Glioblastoma
Google:
"Joseph Antonios"
Mean distance: 42746.4 (cluster 6)
 
Tree Publications Grants Similar researchers PubMed Report error

Parents

Sign in to add mentor
Michael S. Levine research assistant 2007-2011 UCLA
Arnold B. Scheibel research assistant 2009-2011 UCLA
Linda Liau grad student 2013- UCLA

Children

Sign in to add trainee

Collaborators

Sign in to add collaborator
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Everson RG, Hugo W, Sun L, et al. (2024) Author Correction: TLR agonists polarize interferon responses in conjunction with dendritic cell vaccination in malignant glioma: a randomized phase II Trial. Nature Communications. 15: 4800
Everson RG, Hugo W, Sun L, et al. (2024) TLR agonists polarize interferon responses in conjunction with dendritic cell vaccination in malignant glioma: a randomized phase II Trial. Nature Communications. 15: 3882
Everson RG, Hugo W, Sun L, et al. (2023) Dendritic Cell Vaccination in Conjunction with a TLR Agonist Polarizes Interferon Immune Responses in Malignant Glioma Patients. Research Square
Antonios JP, Everson RG, Mochizuki A, et al. (2020) Abstract PR13: Adjuvant TLR-3 administration enhances proinflammatory immune responses and is associated with extended survival in glioblastoma patients treated with dendritic cell vaccination Cancer Immunology Research. 8
Chavez C, Everson R, Orpilla J, et al. (2020) CTIM-18. DENDRITIC CELL VACCINATION IN CONJUNCTION WITH ADJUVANT TLR-3 AGONIST ADMINISTRATION ENHANCES PRO-INFLAMMATORY IMMUNE RESPONSES AND IS ASSOCIATED WITH EXTENDED SURVIVAL IN MALIGNANT GLIOMA PATIENTS Neuro-Oncology. 22: ii36-ii37
Liu F, Cox CD, Chowdhury R, et al. (2019) SPINT2 is hypermethylated in both IDH1 mutated and wild-type glioblastomas, and exerts tumor suppression via reduction of c-Met activation. Journal of Neuro-Oncology
Sun M, Orpilla J, Contreras E, et al. (2019) IMMU-50. SYSTEMIC ADOPTIVE TRANSFER IMMUNOTHERAPY WITH TCR-TRANSDUCED T-CELLS TARGETING NY-ESO-1 FOR MENINGIOMA Neuro-Oncology. 21: vi129-vi130
Davidson TB, Lee AH, Hsu M, et al. (2018) Expression of PD-1 by T cells in malignant glioma patients reflects exhaustion and activation. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research
Everson RG, Antonios JP, Liau LM. (2018) Cell-Based Immunotherapy of Gliomas. Progress in Neurological Surgery. 32: 90-100
Antonios JP, Soto H, Everson RG, et al. (2018) 214 Noninvasive Monitoring of Immunotherapeutic Responses in Glioblastoma Using Novel Imaging Techniques Neurosurgery. 65: 120-120
See more...